Table 1.
Primary antibodies employed in this study
| Antibody | Type | Specificity | Protein Loaded (μg) | Dilution | Source/Reference |
|---|---|---|---|---|---|
| RL2 | Mono- | O-GlcNAc | 10 | 1:2000 | Affinity Bioreagents, Golden, CO, USA |
| CTD110.6 | Mono- | O-GlcNAc | 10 | 1:2000 | Covance, Emeryville, CA, USA |
| Anti-OGT (TI-14) | Poly- | OGT | 5 | 1:2000 | Sigma Aldrich, St. Louis, MO, USA |
| Anti-AKT | Poly- | AKT | 1 | 1:1000 | Cell Signaling Technology, MA, USA |
| Anti-AKT-pT308 | Poly- | AKT-pT308 | 30–50 | 1:500 | Cell Signaling Technology |
| Anti-AKT-pS473 | Poly- | AKT-pS473 | 10 | 1:1000 | Cell Signaling Technology |
| Anti-GSK-3β | Mono- | GSK-3β | 1 | 1:1000 | Cell Signaling Technology |
| Anti-GSK-3β-pS9 | Poly- | GSK-3β-pS9 | 5 | 1:1000 | Cell Signaling Technology |
| Anti-GSK-3α/β | Poly- | Anti-GSK-3α/β | 1 | 1:1000 | Cell Signaling Technology |
| Anti-GSK-3α/β-pS21/9 | Poly- | Anti-GSK-3α/β-pS21/9 | 5 | 1:1000 | Cell Signaling Technology |
| Anti-FoxO1-pS256 | Poly- | FoxO1-pS256 | 20 | 1:1000 | Cell Signaling Technology |
| Anti-FoxO1 | Poly- | FoxO1 | 5 | 1:1000 | Cell Signaling Technology |
| Anti-β-Catenin-pS33/37/T41 | Poly- | β-Catenin-pS33/37/T41 | 10 | 1:1000 | Cell Signaling Technology |
| Anti-β-Catenin | Poly- | β-Catenin | 5 | 1:1000 | Cell Signaling Technology |
| Anti-GAPDH | Poly- | GAPDH | 1 | 1:2000 | Santa Cruz, CA, USA |